Request Demo
Last update 27 Feb 2026
Fosamprenavir/Ritonavir
Last update 27 Feb 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms- |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC37H48N6O5S2 |
InChIKeyNCDNCNXCDXHOMX-XGKFQTDJSA-N |
CAS Registry155213-67-5 |
View All Structures (2)
Related
8
Clinical Trials associated with Fosamprenavir/RitonavirNCT01290211
Open-Label, Fixed-Sequence Study To Estimate The Pharmacokinetic Interaction Between Multiple Dose Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects
NCT01140412
Open-Label, Fixed-Sequence, Crossover Study To Estimate The Pharmacokinetic Interaction Between Multiple Dose Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects
NCT00977301
The Effect of FOsamprenavir/Ritonavir on the Pharmacokinetics of a Single-dose of the Antipsychotic Agent olanZApine (FORZA)
100 Clinical Results associated with Fosamprenavir/Ritonavir
Login to view more data
100 Translational Medicine associated with Fosamprenavir/Ritonavir
Login to view more data
100 Patents (Medical) associated with Fosamprenavir/Ritonavir
Login to view more data
100 Deals associated with Fosamprenavir/Ritonavir
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HIV Infections | Phase 3 | Australia | 01 Mar 2005 | |
| HIV Infections | Phase 3 | Belgium | 01 Mar 2005 | |
| HIV Infections | Phase 3 | Canada | 01 Mar 2005 | |
| HIV Infections | Phase 3 | France | 01 Mar 2005 | |
| HIV Infections | Phase 3 | Germany | 01 Mar 2005 | |
| HIV Infections | Phase 3 | Greece | 01 Mar 2005 | |
| HIV Infections | Phase 3 | Italy | 01 Mar 2005 | |
| HIV Infections | Phase 3 | Spain | 01 Mar 2005 | |
| HIV Infections | Phase 3 | United Kingdom | 01 Mar 2005 | |
| Schizophrenia | Phase 1 | Netherlands | 30 Nov 2009 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | - | rsfwvaziqf(vrkxcfxuiv) = utklzjjlqh ftcqjclsyu (tfhcehaing, 0.7 - 8.6) | - | 01 Aug 2011 | ||
Phase 3 | 212 | ABC+FPV+3TC+RTV (FPV/RTV 1400/100 mg Once Daily (QD) + ABC/3TC FDC 600/300 mg Q) | xvgrgovcds = gderwdrnjb imfgvelckz (hlqircankq, fkaxryeolz - plefsnpgfc) View more | - | 02 Sep 2009 | ||
ABC+FPV+3TC+RTV (FPV/RTV 700/100 mg BID + ABC/3TC FDC 600/300 mg QD) | xvgrgovcds = tcxbcuqjky imfgvelckz (hlqircankq, ystzmxmqek - ddwbdlgcgh) View more | ||||||
Not Applicable | - | - | FPV/r | xnsjdxfkhh(wxnrzbpnkp) = zuelecyfyp cqheitldyg (ahuxlpqmll ) | - | 01 Jan 2007 | |
xnsjdxfkhh(wxnrzbpnkp) = mpbjssqrob cqheitldyg (ahuxlpqmll ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free